After a day of meetings with management, Cantor Fitzgerald analyst Brandon Folkes says that based on Symphony script data so far in 2018, the company is exceeding its execution goals as well as his expectations. The sentiment at the meetings "was positive with a common theme of delving into whether the company has the foundation to continue to execute in 2019 as it has in 2018," Folkes tells investors in a research note. The analyst has increased conviction that "solid execution" in 2019 and beyond is likely to continue, which he believes should drive upward earnings revisions and further upside in BioDelivery shares. Folkes reiterates an Overweight rating on the name with a $5 price target.